CRNX241220C50000
- 6.50
- 0.000.00%
Crinetics Newsroom
Crinetics Pharmaceuticals Grants Stock Options to New Employees Under 2021 Inducement Plan
Express News | Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $87
Crinetics Announces FDA Acceptance of NDA for Paltusotine
Express News | Crinetics Pharmaceuticals Inc - FDA Targets Pdufa Date Sept 25, 2025 for Nda Review Completion
Express News | Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients With Acromegaly
Cushing Syndrome Pipeline Insight 2024, Featuring Key Players Corcept Therapeutics, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals and Key Products Relacorilant, SPI 62 and CRN-04894
Crinetics Price Target Raised to $87 From $80 at JMP Securities
Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX), Halozyme (HALO) and Crinetics Pharmaceuticals (CRNX)
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $82
Promising Outlook for Crinetics Pharmaceuticals' Paltusotine in Phase 3 Trial Drives Buy Rating
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 Loss per Share (Vs US$1.01 Loss in 3Q 2023)
Citi Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $74
Crinetics Pharmaceuticals: Promising Future With Innovative Drug Developments and Strong Financial Position
Crinetics Pharmaceuticals Analyst Ratings
JonesTrading Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $71
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
Piper Sandler Remains a Buy on Crinetics Pharmaceuticals (CRNX)